Zeo ScientifiX Awards $6.4M in Stock Options to Executives and Key Stakeholders
ZEOX sits 42% above its 52-week low of $1.2 on light trading volume (0.3× avg).
Summary
Zeo ScientifiX awarded 3.83 million stock options, valued at $6.4 million, to its CEO, CMO, a major stockholder, and a director, creating significant potential dilution for the micro-cap company.
Key Events · Executive and Board Changes · ZEOX
-
Massive Option Grant
The company awarded 3.83 million stock options to its CEO, CMO, a principal stockholder, and a non-executive director.
-
Significant Potential Dilution
The options have a total potential value of $6.4 million, representing approximately 48% of the company's current market capitalization, indicating substantial future dilution.
-
In-the-Money and Vested Options
Some options are immediately vested and have an exercise price of $1.67, which is slightly below the current stock price of $1.70.
-
Key Recipients
Options were granted to CEO Ian Bothwell, CMO George Shapiro, principal stockholder Greyt Ventures LLC, and non-executive director Chuck Bretz.
Analysis · ZEOX · Life Sciences
Zeo ScientifiX has granted a substantial amount of stock options, totaling 3.83 million shares with an exercise price of $1.67, to its CEO, CMO, a principal stockholder, and a director. The potential value of these options, if exercised, is approximately $6.4 million, which represents a significant portion of the company's $13.2 million market capitalization. This large grant, with some options immediately vested and in-the-money, introduces considerable potential future dilution for existing shareholders.
At the time of this filing, ZEOX was trading at $1.70 on OTC in the Life Sciences sector, with a market capitalization of approximately $13.2M. The 52-week trading range was $1.20 to $2.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.